Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in DREAMM-7 and DREAMM-8 trials still produced median PFS in patients with ≥1 dose delay of ≥12 weeks of 36.6 months and NR, respectively.”
Title: Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials
Authors: Maria-Victoria Mateos, Suzanne Trudel, Hang Quach, Pawel Robak, Meral Beksac, Ludek Pour, Marek Hus, Kihyun Kim, Vera Zherebtsova, Sosana Delimpasi, Tomas Jelínek, Christopher Ward, P. Joy Ho, Vladimir I. Vorobyev, Marcelo Pitombeira Lacerda, Gracia Aparecida Martinez, Ivan Spicka, Jakub Radocha, Michele Cavo, Claudio Cerchione, Chengcheng Fu, Kazuhito Suzuki, Rachel Rogers, Amy Phillips-Jones, Zhaohui Wang, Hena Baig, Jodie Wilkes, Xiaoou L. Zhou, Eric Lewis, Lydia Eccersley, Neal Sule, Prani Paka, Joanna B. Opalinska, Pralay Mukhopadhyay, Vania Tietsche de Moraes Hungria, Meletios Athanasios Dimopoulos
You can read the Full Article on Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
